Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on April 12, 2019, covering events that occurred on April 8 and April 9, 2019. The Company is an emerging growth company incorporated in Nevada, focused on developing drug candidates such as XPro 1595.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document solely discloses upcoming corporate presentations.
Outlook, Management Commentary, and Risks
- Upcoming Presentations: Lesley Probert, Ph.D., Head of Immunology at the Hellenic Pasteur Institute, is scheduled to present on the drug candidate XPro 1595 at the European Conference on Neuroinflammation (April 8-9, 2019).
- Management Presentation: Raymond J. Tesi, Chief Executive Officer, is scheduled to present at the Cambridge Healthtech Institute's Inflammation Inhibitors Conference on April 11, 2019, in San Diego, California.
- Exhibit Status: The press releases regarding these events are furnished as Exhibits 99.1 and 99.2 but are not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the content and data presented in the press releases furnished as Exhibits 99.1 and 99.2.
- Confirm the outcomes of the presentations regarding XPro 1595 at the European Conference on Neuroinflammation.
- Review the CEO's presentation at the Inflammation Inhibitors Conference for updates on the Company's pipeline strategy.